Cargando…

AVP-825 Breath-Powered Intranasal Delivery System Containing 22 mg Sumatriptan Powder vs 100 mg Oral Sumatriptan in the Acute Treatment of Migraines (The COMPASS Study): A Comparative Randomized Clinical Trial Across Multiple Attacks

OBJECTIVE: The objective of this study was to compare the efficacy, tolerability, and safety of AVP-825, an investigational bi-directional breath-powered intranasal delivery system containing low-dose (22 mg) sumatriptan powder, vs 100 mg oral sumatriptan for acute treatment of migraine in a double-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tepper, Stewart J, Cady, Roger K, Silberstein, Stephen, Messina, John, Mahmoud, Ramy A, Djupesland, Per G, Shin, Paul, Siffert, Joao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd 2015
Materias:	Research Submissions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4682470/ https://www.ncbi.nlm.nih.gov/pubmed/25941016 http://dx.doi.org/10.1111/head.12583

Ejemplares similares

A Randomized, Double-Blind, Placebo-Controlled Study of Breath Powered Nasal Delivery of Sumatriptan Powder (AVP-825) in the Treatment of Acute Migraine (The TARGET Study)
por: Cady, Roger K, et al.
Publicado: (2015)

Improved Pharmacokinetics of Sumatriptan With Breath Powered™ Nasal Delivery of Sumatriptan Powder
por: Obaidi, Mohammad, et al.
Publicado: (2013)

Randomized, double-blind, crossover study comparing DFN-11 injection (3 mg subcutaneous sumatriptan) with 6 mg subcutaneous sumatriptan for the treatment of rapidly-escalating attacks of episodic migraine
por: Cady, Roger K., et al.
Publicado: (2017)

Evaluation of the Pharmacokinetic Interaction of Ubrogepant Coadministered With Sumatriptan and of the Safety of Ubrogepant With Triptans
por: Jakate, Abhijeet, et al.
Publicado: (2020)

Breath-powered sumatriptan dry nasal powder: an intranasal medication delivery system for acute treatment of migraine
por: Tepper, Stewart J, et al.
Publicado: (2018)

Treatment satisfaction and efficacy of the rapid release formulation of sumatriptan 100 mg tablets utilising an early intervention paradigm in patients previously unsatisfied with sumatriptan
por: Newman, L C, et al.
Publicado: (2008)

Sumatriptan (50 and 100 mg) in repeated migraine attacks: a patient preference study
por: Zanchin, Georgio, et al.
Publicado: (2000)

Functional Hybrid Nanoemulsions for Sumatriptan Intranasal Delivery
por: Ribeiro, Lígia N. M., et al.
Publicado: (2020)

Harnessing Intranasal Delivery Systems of Sumatriptan for the Treatment of Migraine
por: Assadpour, Sara, et al.
Publicado: (2022)

Human factors validation study of 3 mg sumatriptan autoinjector, for migraine patients
por: Brand-Schieber, Elimor, et al.
Publicado: (2016)

Influence of sumatriptan on the autonomic system during migraine attacks
por: Dalla Volta, G., et al.
Publicado: (2006)

Metabolism of sumatriptan revisited
por: Pöstges, Timo, et al.
Publicado: (2023)

Treatment with sumatriptan 50 mg in the mild phase of migraine attacks in patients with infrequent attacks: a randomised, double-blind, placebo-controlled study
por: Tfelt-Hansen, P., et al.
Publicado: (2006)

A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute treatment of episodic migraine
por: Munjal, Sagar, et al.
Publicado: (2017)

Efficacy of Sumatriptan/Placebo versus Sumatriptan/Propofol Combination in Acute Migraine; a Randomized Clinical Trial
por: Farahmand Rad, Reza, et al.
Publicado: (2022)

A comparison of preference for and efficacy of tablet formulations of sumatriptan (50 mg and 100 mg), naratriptan (2.5 mg), rizatriptan (10 mg), and zolmitriptan (2.5 mg) in the acute treatment of migraine
por: Dahlöf, Carl, et al.
Publicado: (2004)

Efficacy of oxygen inhalation in sumatriptan refractory “high altitude” cluster headache attacks
por: Mampreso, Edoardo, et al.
Publicado: (2009)

Spontaneous splenic infarction associated with sumatriptan use
por: Arora, A., et al.
Publicado: (2006)

Bilateral Renal Infarctions During the Use of Sumatriptan
por: Abramovitz, Blaise, et al.
Publicado: (2018)

Efficacy, Tolerability, and Safety of DFN‐15 (Celecoxib Oral Solution, 25 mg/mL) in the Acute Treatment of Episodic Migraine: A Randomized, Double‐Blind, Placebo‐Controlled Study
por: Lipton, Richard B., et al.
Publicado: (2019)

Sumatriptan 6 mg subcutaneous as an effective migraine treatment in patients with cutaneous allodynia who historically fail to respond to oral triptans
por: Diamond, S., et al.
Publicado: (2007)

In vivo bioavailability studies of sumatriptan succinate buccal tablets
por: Shivanand, K, et al.
Publicado: (2011)

Subcutaneous delivery of sumatriptan in the treatment of migraine and primary headache
por: Moore, Johanna C, et al.
Publicado: (2012)

Effect of CGRP and sumatriptan on the BOLD response in visual cortex
por: Asghar, Mohammad S., et al.
Publicado: (2012)

Formulation and evaluation of bucco-adhesive tablets of sumatriptan succinate
por: Prasanna, R Indira, et al.
Publicado: (2011)

Formulation and evaluation of sublingual tablets containing Sumatriptan succinate
por: Prajapati, Shailesh T, et al.
Publicado: (2012)

Inhibition of voltage-gated sodium channels by sumatriptan bioisosteres
por: Carbonara, Roberta, et al.
Publicado: (2015)

Sumatriptan ameliorates renal injury induced by cisplatin in mice
por: Bazmandegan, Gholamreza, et al.
Publicado: (2019)

Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: an 8-week open-label extension study
por: Landy, Stephen, et al.
Publicado: (2018)

A Phase 1, Randomized, Open‐Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects
por: Albrecht, Detlef, et al.
Publicado: (2020)

Sumatriptan inhibits synaptic transmission in the rat midbrain periaqueductal grey
por: Jeong, Hyo-Jin, et al.
Publicado: (2008)

Does sumatriptan cross the blood–brain barrier in animals and man?
por: Tfelt-Hansen, Peer Carsten
Publicado: (2009)

Sumatriptan and dihydroergotamine in proximal and distal human isolated coronary arteries
por: Labruijere, S, et al.
Publicado: (2013)

EHMTI-0096. Efficacy of sumatriptan: assessment of a possible biomarker
por: Ibrahimi, K, et al.
Publicado: (2014)

Comparative Study of Different Combinational Mucoadhesive Formulations of Sumatriptan-Metoclopramide
por: Jelvehgari, Mitra, et al.
Publicado: (2016)

Pre-treatment with sumatriptan for cilostazol induced headache in healthy volunteers
por: Falkenberg, Katrine, et al.
Publicado: (2018)

Sumatriptan-induced angle-closure glaucoma: A case report
por: Hsu, Cherng-Ru, et al.
Publicado: (2017)

Investigation of sumatriptan and ketorolac trometamol in the human experimental model of headache
por: Ghanizada, Hashmat, et al.
Publicado: (2020)

The Use of Neuroimaging for Predicting Sumatriptan Treatment Response in Patients With Migraine
por: Wu, Jr-Wei, et al.
Publicado: (2022)

Evaluation of 2‐Hour Post‐Dose Efficacy of Lasmiditan for the Acute Treatment of Difficult‐to‐Treat Migraine Attacks
por: Tepper, Stewart J., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0i041fneh16vdsmj2bjo8fbe2r